Key result
Cardiac resynchronization therapy in patients with dilated/end-stage hypertrophic cardiomyopathy did not reduce the combined endpoint of LVAD, cardiac transplant, or death.
Why the study?
Does cardiac resynchronization therapy improve ventricular function or reduce the composite of LVAD, cardiac transplant, or death in patients with end-stage hypertrophic cardiomyopathy?
Cohort (n=18)
No
Does cardiac resynchronization therapy improve ventricular function or reduce the composite of LVAD, cardiac transplant, or death in patients with end-stage hypertrophic cardiomyopathy?
CRT does not appear to improve ventricular function or reduce the need for advanced heart failure therapies in patients with dilated/end-stage hypertrophic cardiomyopathy.
Answers are grounded in this paper and cite their sources.
CRT shows no EF benefit in end-stage HCM; leaves open effects on symptoms or survival and should not yet change practice.
Aims: A dilated/end-stage phase of hypertrophic cardiomyopathy (HCM) is rare but well-recognized. The role for cardiac resynchronization therapy (CRT) in this subset of patients remains unexplored. We aimed to clarify the impact of bi-ventricular pacing CRT in dilated/end-stage HCM. Methods and results: The Mayo Clinic HCM database was interrogated to identify patients with ejection fraction (EF) <50% and CRT. Control subjects were identified in 1:1 manner. Clinical outcomes were determined. Of 2073 patients with HCM, 9 (8 male) had EF <50% and received CRT. The average age at CRT-D implant was 44.8 ± 14.8 years, an average of 17.3 ± 10.3 years after HCM diagnosis. The indication for CRT was based on New York Heart Association class ≥II symptoms (mean 2.7 ± 0.4) and EF <50% in all patients (EF 34.7 ± 7.1% at implant), with electrocardiographic evidence of abnormal ventricular conduction. At 6-month, 12-month, and long-term follow-up, EF was 39.9 ± 8.4%, 37.9 ± 9.8%, and 33.3 ± 7.6%, respectively (P > 0.05 for all). There was no difference in the combined end-point of left ventricular assist device (LVAD), cardiac transplant, or death between groups (P = 0.90). At last follow-up [mean duration 12.9 ± 8.3 (median 10.7) years], 8 (89%) in the CRT group were alive. Three and 2 patients underwent LVAD implantation and cardiac heart transplantation, respectively, 15.0 ± 10.1 years from HCM diagnosis and 2.6 ± 0.9 years from CRT implant. In the control group, 4 (44.4%) patients were alive at last follow-up [mean duration 12.0 ± 7.1 (median 12.7) years]. One patient each had LVAD and cardiac transplant. Conclusions: CRT in patients with dilated/end-stage HCM does not appear to confer a salutary effect on ventricular function. In medium-term follow-up, however, left ventricular function did not appear to deteriorate further, yet advanced heart failure therapy was common in this group.
No takes yet. Share an insight, caveat, or question.
Killu et al. (2016) conducted a cohort in Dilated/end-stage hypertrophic cardiomyopathy (n=18). Cardiac resynchronization therapy (CRT) vs. Matched controls without CRT was evaluated on Combined end-point of left ventricular assist device (LVAD), cardiac transplant, or death (p=0.90). Cardiac resynchronization therapy in patients with dilated/end-stage hypertrophic cardiomyopathy did not reduce the combined endpoint of LVAD, cardiac transplant, or death.
Synapse has enriched 10 related papers. Consider them for comparative context: